Results 91 to 100 of about 3,343,278 (165)

Mucuna pruriens as a Sustainable Functional Food: Applications From Seed to Product

open access: yesModern Agriculture, Volume 4, Issue 2, December 2026.
This review highlights Mucuna pruriens as a nutrient‐rich legume with significant nutritional, therapeutic, and agricultural value. Its protein‐rich seeds contain essential minerals and L‐DOPA, but high antinutritional compounds require effective processing before consumption.
Crossby Osei Tutu   +10 more
wiley   +1 more source

Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia

open access: yes, 2010
The aim of the present study was to evaluate the role of the nitric oxide/cyclic guanosine monophosphate pathway in corticostriatal long-term depression induction in a model of levodopa-induced dyskinesia in experimental parkinsonism.
Calabresi, Paolo   +22 more
core   +1 more source

μ- and δ-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

open access: yes, 2001
Long-term treatment of Parkinson's disease with levodopa is complicated by the emergence of involuntary movements, known as levodopa-induced dyskinesia.
Crossman, Alan R.   +3 more
core   +1 more source

Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia

open access: yes, 2018
Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy.
Novello S.   +12 more
core   +2 more sources

Hyperdopaminergic Manifestations in Parkinson’s Disease: Correlation between Impulse Control Disorders and Levodopa- Induced Dyskinesia [PDF]

open access: yesAin Shams Medical Journal
Objective: To explore the relationship between levodopa-induced dyskinesia and impulse control disorders (ICDs) inParkinson’s disease (PD), exploring the hyperdopaminergic motor and non-motor state.Methods: A cross-sectional study was conducted on 30 PD ...
ALIA MANSOUR   +4 more
doaj   +1 more source

Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?

open access: yes, 2018
BACKGROUND: It remains controversial whether late levodopa administration is a reasonable approach to reducing the risk of levodopa-induced dyskinesia in Parkinson's disease. OBJECTIVE: This study aimed to investigate the effects of levodopa sparing
이필휴   +4 more
core   +1 more source

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia [PDF]

open access: yes, 2016
BackgroundThis phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor 7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia.
Jaeger, J   +65 more
core   +1 more source

No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician’s Point of View

open access: yesNeurology International
Background: The term dyskinesia describes involuntary movements of the face, body and extremities. Frequently, they appear following and in relation with prior oral long-lasting and high-dose levodopa therapy in Parkinson’s disease patients.
Thomas Müller
doaj   +1 more source

Transcriptome‐Based Identification of ZZEF1 and ENTPD5 as Candidate Genes for Dystonia

open access: yes
Movement Disorders, EarlyView.
Alexandra Rudnik   +15 more
wiley   +1 more source

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.

open access: yes, 2010
OBJECTIVE:: Striatal serotonin projections have been implicated in levodopa-induced dyskinesia by providing an unregulated source of dopamine release.
Dovero, Sandra   +18 more
core   +1 more source

Home - About - Disclaimer - Privacy